Table. Evidence-based negative recommendations for COVID-19 drug therapy.

Pharmacological intervention	Recommendation for hospitalized patients with COVID-19	Mortality reduction absolute and relative risk [95% CI]	Quality of evidence (for mortality)
Convalescent plasma	Should not	23.7→ 23.3 % [21.8; 24.9] RR 0.98 [0.92; 1.05]	High
Ivermectin	Should not	9.6→ 5.8 % [1.3; 24.1] RR 0.6 (0.14−2.51)	Very low
Vitamin D	Should not	Not pooled (heterogeneity)	Very low
Azithromycin	Should not	22.3→ 21.9 % [20.1; 23.6] RR 0.98 [0.9; 1.06]	High
Bamlanivimab monotherapy	Should not	2.7→ 3.8 % [1.1; 13.0] RR 1.39 [0.4; 4.83]	Low
Anakinra	Should not	23.6→ 21.9 % [11.1; 43.2] RR 0.93 [0.47; 1.83]	Moderate
Colchicin	Should not	20.7→ 20.7 % [19.3; 22.4] RR 1 [0.93; 1.08]	Moderate

CI, confidence interval; RR, relative risk